Get the Stockscreener App
91.57
0.39%
-0.36
After Hours:
91.57
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $91.57, with a volume of 3.56M.
It is down -0.39% in the last 24 hours and up +1.55% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$91.93
Open:
$92.39
24h Volume:
3.56M
Relative Volume:
0.68
Market Cap:
$283.92B
Revenue:
$58.07B
Net Income/Loss:
$9.40B
P/E Ratio:
30.41
EPS:
3.0113
Net Cash Flow:
$9.87B
1W Performance:
-1.43%
1M Performance:
+1.55%
6M Performance:
+28.74%
1Y Performance:
+39.00%
1-Day Range:
$91.17
$92.45
1-Week Range:
$91.17
$92.89
52-Week Range:
$61.24
$94.02
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
91.57 | 285.04B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
The Truth About AstraZeneca plc: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Can AstraZeneca PLC ZEG stock sustain institutional flowsMarket Weekly Review & Daily Stock Trend Reports - moha.gov.vn
Key facts: AstraZeneca lowers drug prices for Medicaid; reports share count - TradingView — Track All Markets
AstraZeneca reports total voting rights of 1.55 billion shares - Investing.com
AstraZeneca reports total voting rights of 1.55 billion shares By Investing.com - Investing.com South Africa
Biological Therapies for Cancer Global Markets Report 2025-2030: Merck, BMS, Roche, AstraZeneca, Johnson & Johnson, and Novartis Drive Growth Through Pipeline Expansion and Strategic CollaborationsResearchAndMarkets.com - FinancialContent
Q4 EPS Estimates for AstraZeneca Boosted by Zacks Research - MarketBeat
My Personal CFO LLC Acquires Shares of 38,411 AstraZeneca PLC $AZN - MarketBeat
Zacks Research Raises Earnings Estimates for AstraZeneca - MarketBeat
Invest Outside the U.S. With These Top International ETFs - The Motley Fool
25,322 Shares in AstraZeneca PLC $AZN Purchased by Moody Lynn & Lieberson LLC - MarketBeat
The Zacks Analyst Blog Highlights Berkshire Hathaway, AstraZeneca, Intel, Kingsway Financial and BK Technologies - Yahoo Finance
Smith Salley Wealth Management Raises Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Top Stock Reports for Berkshire Hathaway, AstraZeneca & Intel - Yahoo Finance
Ethic Inc. Acquires 11,638 Shares of AstraZeneca PLC $AZN - MarketBeat
Why AstraZeneca PLC (Common Stock) (ZEGA) stock appears on watchlistsHigh Frequency Trading Trends & Free Powerful Profit Generation - bollywoodhelpline.com
Valicenti Advisory Services Inc. Has $4.66 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
DAVENPORT & Co LLC Increases Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (AZN) Stock Price Today - CoinMarketCap
AstraZeneca stock holds steady as mixed news and technicals limit major moves - Traders Union
Robbins Farley Purchases 27,582 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Reaches Settlement With MSN Labs Over Cancer Drug - Bloomberg Law News
Swedbank AB Buys 286,904 Shares of AstraZeneca PLC $AZN - MarketBeat
LSEG, Rolls-Royce, AstraZeneca and Rightmove spotlighted as investment bank eyes potential winners for 2026 - Proactive financial news
Here's Why Astrazeneca (AZN) is a Strong Value Stock - Yahoo Finance
AstraZeneca’s NSCLC combo fails to meet primary endpoint in Phase III trial - Clinical Trials Arena
FDA Flags Deadly Risks, AstraZeneca Pulls Andexxa From US Market - Sahm
AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial - Sahm
Jacobio signs $1.9B deal with Astrazeneca for pan-KRAS inhibitor - BioWorld MedTech
AstraZeneca Sues US Over Drugs for Medicare Price Cuts Round 2 - Bloomberg Law News
AstraZeneca (AZN) to Withdraw Andexxa from U.S. Market by Year's End - GuruFocus
AstraZeneca reports Phase III trial of ceralasertib and Imfinzi did not meet main goal - Investing.com Nigeria
AstraZeneca’s Synthetic Lethality Drug Combo Fails In Phase III Trial - Citeline News & Insights
AstraZeneca director Nazneen Rahman sells 297 shares in London transaction - Investing.com
AstraZeneca director Nazneen Rahman sells 297 shares in London transaction By Investing.com - Investing.com South Africa
AstraZeneca (AZN) Benefits as U.S. Government Strikes Pharmaceutical Deals - GuruFocus
AstraZeneca (AZN) gains 10th FDA Breakthrough Therapy nod for Enhertu in HER2-positive early breast cancer - Stock Titan
AstraZeneca (LON:AZN) Insider Sells £40,083.12 in Stock - MarketBeat
FDA grants breakthrough therapy designation to AstraZeneca’s ENHERTU for HER2-positive early breast cancer - Investing.com UK
AstraZeneca PLCEnhertu granted BTD for post-neoadjuvant early BC - Research Tree
AstraZeneca Starts Phase 3 Post-Surgery Endometrial Cancer Trial - marketscreener.com
Jacobio Strikes New Cancer Drug Deal with AstraZeneca - marketscreener.com
AstraZeneca, Jacobio Pharma Sign Global License Deal for Pan-KRAS Inhibitor - marketscreener.com
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView — Track All Markets
AstraZeneca (AZN) Advances Phase 3 Trial for Enhertu in Endometr - GuruFocus
AstraZeneca pulls Andexxa from US market after post-marketing fatalities - Pharmaceutical Technology
Astrazeneca Says Phase 3 Lung Cancer Trial Failed to Meet Primary Endpoint of Overall Survival - marketscreener.com
AstraZeneca, Daiichi Sankyo's Enhertu Gets Breakthrough Therapy Designation in the US - marketscreener.com
AstraZeneca gets fresh designation for Enhertu while Imfinzi trial fizzles - Vox Markets
AstraZeneca’s lung cancer trial fails to meet primary endpoint - Investing.com
AstraZeneca’s Enhertu gets FDA Breakthrough Therapy status for breast cancer - Investing.com
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):